Ozempic vs Mounjaro: Complete Comparison | GlucoseVerified

Quick Comparison

Ozempic (semaglutide): GLP-1 only, 1-2% A1C reduction, ~15% weight loss Mounjaro (tirzepatide): GLP-1 + GIP, 2-2.5% A1C reduction, ~20% weight loss

Overview

Ozempic and Mounjaro are both injectable medications for type 2 diabetes that also promote significant weight loss. While they work similarly, Mounjaro is a newer drug with a dual mechanism that appears to be more potent.

Mechanism of Action

How They Work

Medication	Mechanism	Effect
Ozempic	GLP-1 receptor agonist only	Increases insulin, decreases glucagon, slows gastric emptying, reduces appetite
Mounjaro	GLP-1 + GIP dual agonist	Same as GLP-1 plus additional GIP effects on fat metabolism and insulin sensitivity

Efficacy Comparison

Head-to-Head Results (SURPASS-2 Trial)

Outcome	Ozempic 1mg	Mounjaro 15mg
A1C Reduction	-1.86%	-2.46%
Weight Loss	-5.7 kg	-11.2 kg
Patients Reaching A1C <7%	79%	92%
Patients Losing >5% Weight	58%	86%

Dosing

Ozempic: Start 0.25mg weekly → 0.5mg → 1mg → 2mg max
Mounjaro: Start 2.5mg weekly → 5mg → 7.5mg → 10mg → 12.5mg → 15mg max
Both: Once weekly injection, can be any day
Dose escalation helps minimize GI side effects

Side Effects

Both medications have similar side effect profiles:

Nausea (most common, usually improves)
Vomiting
Diarrhea
Constipation
Abdominal pain
Injection site reactions

Serious but Rare Risks

• Pancreatitis (both) • Thyroid tumors (boxed warning for both) • Gallbladder problems • Kidney problems • Diabetic retinopathy worsening (with rapid glucose improvement)

Who Should Consider Which?

Ozempic May Be Better For:

Those who have tolerated GLP-1s before
Patients who prefer an established medication
When Mounjaro is not covered by insurance
Patients satisfied with moderate weight loss goals

Mounjaro May Be Better For:

Patients needing maximum A1C reduction
Those prioritizing weight loss
Patients who have not achieved goals on GLP-1s alone
When aggressive treatment is indicated

Cost and Access

Both are expensive without insurance (approximately $900-1000/month). Insurance coverage varies significantly. Both manufacturers offer savings programs for eligible patients.

Important Considerations

Both are contraindicated in personal/family history of medullary thyroid cancer or MEN2
Do not use in type 1 diabetes or diabetic ketoacidosis
Use caution in patients with gastroparesis
May affect absorption of oral medications
Long-term effects beyond current trial data unknown

Medication

Mechanism

Effect

Ozempic

GLP-1 receptor agonist only

Increases insulin, decreases glucagon, slows gastric emptying, reduces appetite

Mounjaro

GLP-1 + GIP dual agonist

Same as GLP-1 plus additional GIP effects on fat metabolism and insulin sensitivity

Outcome

Ozempic 1mg

Mounjaro 15mg

A1C Reduction

-1.86%

-2.46%

Weight Loss

-5.7 kg

-11.2 kg

Patients Reaching A1C <7%

79%

92%

Patients Losing >5% Weight

58%

86%

Side Effects

Both medications have similar side effect profiles:

Nausea (most common, usually improves)

Vomiting

Diarrhea

Constipation

Abdominal pain

Injection site reactions

Serious but Rare Risks

• Pancreatitis (both) • Thyroid tumors (boxed warning for both) • Gallbladder problems • Kidney problems • Diabetic retinopathy worsening (with rapid glucose improvement)

Who Should Consider Which?

Ozempic May Be Better For:

Those who have tolerated GLP-1s before

Patients who prefer an established medication

When Mounjaro is not covered by insurance

Patients satisfied with moderate weight loss goals

Mounjaro May Be Better For:

Patients needing maximum A1C reduction

Those prioritizing weight loss

Patients who have not achieved goals on GLP-1s alone

When aggressive treatment is indicated